title: Evidence of anti-proliferative activities in blue mussel (Mytilus edulis) by-products.
abstract: Shellfish waste components contain significant levels of high quality protein and are therefore a potential source for biofunctional high-value peptides. The feasibility of applying a pilot scale enzymatic hydrolysis process to whole Mytilus edulis and, by fractionation, recover hydrolysates presenting a biological activity of interest, was evaluated. Fractions were tested on four immortalized cancerous cell lines: A549, BT549, HCT15 and PC3. The 50 kDa fraction, enriched in peptides, presented anti-proliferative activity with all cell lines and results suggest a bioactive molecule synergy within the fraction. At a protein concentration of 44 µg/mL, the 50 kDa fraction induced a mortality of 90% for PC3, 89% for A549, 85% for HCT15 and of 81% for BT549 cell lines. At the low protein concentration of only 11 µg/mL the 50 kDa fraction still entails a cell mortality of 76% for A549 and 87% for PC3 cell lines. The 50 kDa fraction contains 56% of proteins, 3% of lipids and 6% of minerals on a dry weight basis and the lowest levels detected of taurine and methionine and highest levels of threonine, proline and glycine amino acids. The enzymatic hydrolysis process suggests that Mytilus edulis by-products should be viewed as high-valued products with strong potential as anti-proliferative agent and promising active ingredients in functional foods.
authors.affiliation: Department of Biology, Chemistry and Geography, University of Quebec at Rimouski, 300 Allée des Ursulines, Rimouski, QC G5L 3A1, Canada. lucie_beaulieu@uqar.qc.ca
authors.forename: Lucie
authors.initials: L
authors.lastname: Beaulieu
authors.forename: Jacinthe
authors.initials: J
authors.lastname: Thibodeau
authors.forename: Claudie
authors.initials: C
authors.lastname: Bonnet
authors.forename: Piotr
authors.initials: P
authors.lastname: Bryl
authors.forename: Marie-Elise
authors.initials: ME
authors.lastname: Carbonneau
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000302:isolation & purification / Q000494:pharmacology*; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects*; D005240:Feasibility Studies; D006801:Humans; D006868:Hydrolysis; D049880:Mytilus edulis / Q000378:metabolism*; D009369:Neoplasms / Q000188:drug therapy* / Q000473:pathology; D010865:Pilot Projects
chemical_list: D000970:Antineoplastic Agents
references.citation: J Exp Biol. 1999 Dec;202(Pt 23):3285-94
references.pmid: 10562511
references.citation: Curr Top Dev Biol. 2008;80:209-76
references.pmid: 17950376
references.citation: J Nat Prod. 2004 Aug;67(8):1216-38
references.pmid: 15332835
references.citation: J Natl Cancer Inst. 1991 Jun 5;83(11):757-66
references.pmid: 2041050
references.citation: Curr Pharm Des. 2003;9(16):1297-308
references.pmid: 12769738
references.citation: Methods Mol Biol. 2000;159:1-7
references.pmid: 11050712
references.citation: Bioresour Technol. 2006 Mar;97(5):762-9
references.pmid: 16324842
references.citation: Bioresour Technol. 2009 Jul;100(13):3332-42
references.pmid: 19286372
references.citation: FEBS J. 2008 Sep;275(18):4479-89
references.pmid: 18671732
references.citation: Crit Rev Food Sci Nutr. 2008 May;48(5):430-41
references.pmid: 18464032
references.citation: J Natl Cancer Inst. 1990 Jul 4;82(13):1107-12
references.pmid: 2359136
references.citation: Am J Physiol. 1984 Aug;247(2 Pt 2):R346-55
references.pmid: 6540526
references.citation: Evid Based Complement Alternat Med. 2011;2011:879585
references.pmid: 19491143
references.citation: J Nat Prod. 2003 Jul;66(7):1022-37
references.pmid: 12880330
references.citation: J Zhejiang Univ Sci B. 2006 Feb;7(2):90-8
references.pmid: 16421963
references.citation: Curr Pharm Des. 2007;13(8):773-91
references.pmid: 17430180
references.citation: Comp Biochem Physiol A Mol Integr Physiol. 2006 Oct;145(2):204-13
references.pmid: 16876449
references.citation: Anticancer Agents Med Chem. 2009 May;9(4):457-70
references.pmid: 19442044
references.citation: Can J Biochem Physiol. 1959 Aug;37(8):911-7
references.pmid: 13671378
references.citation: J Mol Evol. 2011 Jun;72(5-6):531-46
references.pmid: 21643827
references.citation: Gene. 2008 Jan 15;407(1-2):130-8
references.pmid: 17976928
references.citation: Science. 1981 May 29;212(4498):1038-40
references.pmid: 17779975
references.citation: Biol Rev Camb Philos Soc. 2010 Nov;85(4):757-75
references.pmid: 20105155
references.citation: Eur J Cancer. 2008 Nov;44(16):2357-87
references.pmid: 18701274
references.citation: Curr Opin Clin Nutr Metab Care. 2006 Nov;9(6):728-33
references.pmid: 17053427
references.citation: J Natl Cancer Inst. 1990 Jul 4;82(13):1113-8
references.pmid: 2359137
references.citation: Mar Biotechnol (NY). 2007 Nov-Dec;9(6):661-81
references.pmid: 17990038
references.citation: FEBS Lett. 2000 Dec 15;486(3):185-90
references.pmid: 11119700
references.citation: J Biol Chem. 1996 Sep 6;271(36):21808-13
references.pmid: 8702979
references.citation: Environ Pollut. 2003;126(3):407-16
references.pmid: 12963304
references.citation: J Dairy Sci. 2000 Jun;83(6):1187-95
references.pmid: 10877382
references.citation: Mol Cancer Ther. 2005 Feb;4(2):333-42
references.pmid: 15713904